HER2-Positive Breast Cancer: A Review of Data from the SABCS 2021 Virtual Meeting - Episode 3

SABCS 2021: Brain Metastases Updates in Breast Cancer

, , ,

Focusing on datasets from the SABCS 2021 Virtual Meeting, panelists consider novel approaches to the management of brain metastases in breast cancer.

EP. 1: Coming Soon, HER2-Positive Breast Cancer: A Review of Data from the SABCS 2021 Virtual Meeting
EP. 2: SABCS 2021: Updates in Metastatic Breast Cancer
Now Viewing
EP. 3: SABCS 2021: Brain Metastases Updates in Breast Cancer
EP. 4: SABCS 2021: Novel Approaches to Breast Cancer Management

Data from the following clinical trials are discussed:

  • PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis in HER2+ breast cancer: Results from TBCRC049, a phase 2 nonrandomized study
  • PD4-04: Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB)
  • P1-18-26: Intracranial efficacy of tucatinib, palbociclib, and letrozole combination in patients with HR+/HER2+ breast cancer and brain metastases
  • P1-21-03: Efficacy of tyrosine kinase inhibitors (TKIs) in the treatment of patients with HER2+ breast cancer with or without brain metastases: a systematic review and meta-analysis
  • OT1-13-01: HER2CLIMB-04: phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases